Minimally Invasive Treatment Combined With Cytokine-induced Killer Cells Therapy Lower the Short-term Recurrence Rates of Hepatocellular Carcinomas

• DOI: 10.1097/cji.0b013e31815a121b
• Publication Date: 2009-03-05T04:21:22Z
• Authors: De-Sheng Weng; Jun Zhou; Qi-Ming Zhou; Ming Zhao; Qi-Jing Wang; Li-Xi Huang; Yong-Qiang Li; Shi-Ping Chen; Pei-Hong Wu; Jian-Chuan Xia
• Keywords: Cytokine-induced killer cell; Adjuvant Therapy

The recurrence of hepatocellular carcinoma (HCC) after minimally invasive therapy is frequent. Adoptive immunotherapy thought to be an effective method lower and metastasis rates malignant tumors. Therefore, 85 HCC patients transcatheter arterial chemoembolization radiofrequency ablation were randomized group no adjuvant group. Autologous cytokine-induced killer (CIK) cells transfused via hepatic artery the patients. alteration levels lymphocyte subsets in peripheral blood was examined by flow cytometry. All screened computed tomography every 2 months observe tumor recurrent conditions. After CIK cell infusions, percentages CD3+, CD4+, CD56+, CD3+CD56+ cells, CD4+/CD8+ ratio increased from 68.6±11.0%, 31.1±9.0%, 15.6±7.9%, 5.2±3.1%, 1.1±0.5 70.7±10.1%, 33.5±8.0%, 18.4±9.4%, 5.9±2.8%, 1.3±0.7, respectively (P<0.05); whereas percentage CD8+ decreased 31.1±7.8% 28.6±8.3% (P<0.05). 1-year 18-month study 8.9% 15.6%, compared with 30.0% 40.0% control (both P value <0.05). data suggest that transfusion treatment. It can boost immunologic function plays important role reducing rate HCC.